The Drug Cost Controversy, Part 2: What's Next?

Description

Federal and state leaders are pursuing ways to reform drug pricing and reimbursement amid competing ideas and pressure from patients across the country. Join this presentation to get a glimpse into the future. Experts will outline trends and events—along with legal reforms currently on the table—predicted to inform pricing in 2020 and beyond.  

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to: 

  1. Recite trends and themes in drug pricing and reimbursement policy, including federal and state initiatives to address PBM rebates, PBM gag clauses, manufacturer price increases, and transparency. 
  2. Discuss Medicare Part B and D developments, including the International Index Pricing Model; and Medicaid, including state waivers for outcome-based contracts.
  3. Analyze regulatory hurdles for value-based contracting for pharmaceuticals.

Technician Learning Objectives

At the completion of this knowledge-based activity, participants will be able to: 

  1. Recite trends and themes in drug pricing and reimbursement policy, including federal and state initiatives to address PBM rebates, PBM gag clauses, manufacturer price increases, and transparency. 
  2. Discuss Medicare Part B and D developments, including the International Index Pricing Model; and Medicaid, including state waivers for outcome-based contracts.
  3. Analyze regulatory hurdles for value-based contracting for pharmaceuticals.
 
 
 
Speakers:
Mara
Mara Mitchel, NA
Director
BRG
 
Alan
Alan Arville, J.D.
Partner
Epstein Becker & Green, PC
 
Learning Level: Level 2
Track: Pharmacy Law and Regulations
Session Time Slot(s): 
Date: 
Sunday, March 22
Time: 
2:30 PM - 3:45 PM
Room: 
Gaylord National Resort - National Harbor 10-11
CEUs Pharmacist: 0.125
CEUs Pharmacy Technician: 0.125
Activity Type:
Knowledge-based